checkAd
    Startseite > Aktien > GRI Bio > Nachrichten
    GRI Bio Aktie
    0,4055
     
    USD
    +1,12 %
    +0,0045 USD
    Letzter Kurs 02:00:00 NYSE
    0,4001
     
    USD
    800 STK
    Geldkurs 22:02:00
    0,4110
     
    USD
    1.000 STK
    Briefkurs 22:02:00
    ISIN: US3622AW2059 · SYM: GRI · USA

    Neueste Nachrichten

    GRI Bio Announces Pricing of $5.5 Million Public Offering
    02.02.24 · globenewswire · GRI Bio
    GRI Bio Announces Reverse Stock Split
    26.01.24 · globenewswire · GRI Bio
    GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
    27.11.23 · globenewswire · GRI Bio
    GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    15.11.23 · globenewswire · GRI Bio
    GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
    31.10.23 · globenewswire · GRI Bio
    GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
    19.10.23 · globenewswire · GRI Bio
    GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
    17.10.23 · globenewswire · GRI Bio
    GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
    11.10.23 · globenewswire · GRI Bio
    GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
    05.10.23 · globenewswire · GRI Bio
    GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    06.09.23 · globenewswire · GRI Bio
    IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?
    01.09.23 · Accesswire · GRI Bio
    GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
    23.08.23 · globenewswire · GRI Bio